BOARD OF DIRECTORS
GERALD MÖLLER
He has over 40 years’ experience in the pharmaceutical and diagnostics industry. He served as CEO in Boehringer Mannheim and as Head of Development and Strategic Marketing Pharmaceuticals in Roche. He has been an investment advisor at HBM Partners for 12 years. He was also a board member with Illumina Inc. until 2015. Currently he is in the Board of various Life Science companies.
PAUL KINNON
CEO & Member of the board
Paul has over 30 years of experience in the global life sciences industry, with the past 20 years of his executive career focused on Clinical Diagnostics and innovative products to improve patients’ lives. He has held leadership positions within PredictImmune, Transgenomic, ZyGEM Corp., Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, raising more than $70m in funding, creating global partnerships and increasing shareholder return. Paul has spent half of his career living and working in the USA running global businesses, which gives him a novel and unique outlook on the global industry.
Diadem US Inc
DIANA SARACENI
She is Partner of Panakes one of the major Med Tech venture investors in Europe, investor and major shareholder of Diadem srl. She brings 20 years of experience in venture investments on a large portfolio of successful companies.
Diadem US Inc
MARIO SCUDERI
Member of the board
Senior Partner & Co-Responsabile Fondo Evoluzione at CDP Venture Capital SGR – Fondo Nazionale Innovazione. Kauffman. Experienced Investment Manager in Venture Capital Funds. Board member of portfolio companies. Passionate about new tech and great founders. Established International Network within the Venture Capital Industry.
RON EPSTEIN
Member of the board
Dr. Robert Epstein is a physician epidemiologist with an interest in accelerating the adoption of true innovations of novel healthcare solutions. He currently serves on the Boards of Directors of Illumina (ILMN), Fate Therapeutics (FATE), and Veracyte (VCYT), and most recently was Chairman of Decipher Biosciences prior to its acquisition in 2021.